Innovating Works

GIL

Desconocido
ELBA: European Liquid Biopsies Academy Towards widespread clinical application of blood based diagnosti... GILUPI GMBH participó en un H2020: H2020-MSCA-ITN-2017 Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensiti...
2017-08-30 - 2022-09-30 | Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... GILUPI GMBH participó en un FP6: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | Financiado
CanDo: A CANcer Development mOnitor GILUPI GMBH participó en un FP7: Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop...
Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... GILUPI GMBH participó en un FP7: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.